Connect with us

Technology

NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS

Published

2 years ago

on

TOTAL REVENUE OF $222.3 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $178.0 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 25%HOSPITAL DIVISION VISITS OF 122,944 FOR THE FIRST NINE MONTHS OF 2024 VS. VISITS OF 102,798 FOR THE SAME PERIOD IN 2023, AN INCREASE OF 20%HOSPITAL DIVISION OPERATING INCOME OF $54.7 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $21.1 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 159%NET CASH FROM OPERATING ACTIVITIES OF $23.1 MILLION FOR THE FIRST NINE MONTHS OF 2024COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOW

HOUSTON, Nov. 7, 2024 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in ten states and primary care-centric, risk-bearing physician networks, today announced third quarter 2024 financial results for the three and nine months ended September 30, 2024.

Financial Highlights for the Three Months Ended September 30, 2024:

Total revenue of $78.8 million as compared to total revenue of $62.7 million for the three months ended September 30, 2023, an increase of 26%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 20.7% in 2024 compared to the same period in 2023.Operating income (including the negative impact of a $2.0 million non-cash stock-based compensation expense) for the three months ended September 30, 2024 was $9.7 million, compared to an operating loss of approximately $0.8 million for the three months ended September 30, 2023, representing a $10.5 million improvement quarter over quarter.Net loss attributable to Nutex Health of $8.8 million in the three months ended September 30, 2024 as compared to a net loss attributable to Nutex Health of $5.5 million for the three months ended September 30, 2023. This $8.8 million amount includes a $6.7 million non-cash loss on warrant liability as well as the $2.0 million non-cash stock-based compensation expense noted above.EBITDA attributable to Nutex Health of $4.3 million, as compared to EBITDA attributable to Nutex Health of $1.2 million for the three months ended September 30, 2023.Adjusted EBITDA attributable to Nutex Health of $13.5 million, as compared to Adjusted EBITDA attributable to Nutex Health of $1.3 million for the three months ended September 30, 2023, an increase of 938%.Total visits from the Hospital Division were 41,668 for the third quarter 2024, as compared to 37,443 for the third quarter 2023, an increase of 4,225 or 11.3%. Of this visit growth, mature hospitals increased by 3.8% in 2024 compared to the same period in 2023.

Financial Highlights for the Nine Months Ended September 30, 2024:

Total revenue of $222.3 million as compared to total revenue of $178.0 million for the nine months ended September 30, 2023, an increase of approximately 25%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 13.5% in 2024 compared to 2023.Operating income for the nine months ended September 30, 2024 was $16.4 million compared to an operating loss of $5.6 million for the nine months ended September 30, 2023, representing a $22.0 million improvement year over year.Net loss attributable to Nutex Health of $9.5 million as compared to net loss attributable to Nutex Health of $14.2 million for the nine months ended September 30, 2023. This $9.5 million amount includes non-cash items of $10.2 million (non-cash stock-based compensation expense of $2.0 million, non-cash impairment of assets of $3.9 million, non-cash impairment of goodwill of $3.2 million and $1.1 million non-cash loss on warrant liability) in the first nine months of 2024, while the $14.2 million amount includes non-cash stock-based compensation expense of $2.2 million in the first nine months of 2023.EBITDA attributable to Nutex Health of $19.9 million, as compared to EBITDA attributable to Nutex Health of $5.3 million for the nine months ended September 30, 2023.Adjusted EBITDA attributable to Nutex Health of $30.1 million, as compared to Adjusted EBITDA attributable to Nutex Health of $7.7 million for the nine months ended September 30, 2023, an increase of 290%.Total visits from the Hospital Division were 122,944 for the nine months ended September 30, 2024, as compared to 102,798 for the same period in 2023, an increase of 20,146 or 19.6%. Of this visit growth, mature hospitals increased by 7.7% in the nine months ended September 30, 2024 compared to the same period in 2023.Net cash from operating activities of $23.1 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company had total assets of $438.5 million, including cash and cash equivalents of $46.9 million and long-term debt of $26.8 million.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

“We are pleased to report 25% revenue growth, Adjusted EBITDA attributable to Nutex Health of $13.5 million and a 209% increase in gross profit to $21.9 million in the third quarter ended September 30, 2024, showing our continued focus on top line growth, increasing cash flow as well as improving profitability,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“Nutex Health had another outstanding quarter. The strategic and operational decisions we have made over the last nine months are driving this strong performance, as demonstrated by another quarter of year-over-year growth in revenue, EBITDA and Adjusted EBITDA as well as incremental growth in cash flow. We are confident that our momentum will continue and plan on growing our hospital and population health divisions responsibly as we drive value for our shareholders,” stated Warren Hosseinion, M.D., President of Nutex Health.

“The four de-novo hospitals that we opened in 2023 are ramping up nicely, resulting in strong year-over-year growth in both revenue and patient volume. Volumes and revenue continue to increase among our mature hospitals, both on the outpatient side as well as the inpatient side, which still have excess capacity. Our average payment by insurers of patient claims also increased, a trend we are optimistic will persist as we continue to work the NSA (No Surprises Act) claims through the Independent Dispute Resolution process,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s Third Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2024

December 31, 2023

Assets

Current assets:

Cash and cash equivalents

$

46,909,281

$

22,002,056

Accounts receivable

62,745,336

58,624,301

Accounts receivable – related parties

3,602,189

4,152,068

Inventories

2,259,168

3,390,584

Prepaid expenses and other current assets

4,279,360

2,679,394

Total current assets

119,795,334

90,848,403

Property and equipment, net

78,246,467

81,387,649

Operating right-of-use assets

11,442,369

11,853,082

Finance right-of-use assets

198,462,381

176,146,329

Intangible assets, net

15,855,392

20,512,636

Goodwill, net

13,918,719

17,066,263

Other assets

767,942

431,135

Total assets

$

438,488,604

$

398,245,497

Liabilities and Equity

Current liabilities:

Accounts payable

$

10,320,933

$

18,899,196

Accounts payable – related parties

6,342,883

6,382,197

Lines of credit

3,384,517

3,371,676

Current portion of long-term debt

10,499,532

10,808,721

Operating lease liabilities, current portion

2,060,758

1,579,987

Finance lease liabilities, current portion

5,261,458

4,315,979

Accrued expenses and other current liabilities

29,688,665

12,955,296

Total current liabilities

67,558,746

58,313,052

Long-term debt, net

26,801,811

26,314,733

Warrant liability

5,715,143

–

Operating lease liabilities, net

14,307,320

15,479,639

Finance lease liabilities, net

240,924,194

213,886,213

Deferred tax liabilities

3,402,965

5,145,754

Total liabilities

358,710,179

319,139,391

Commitments and contingencies

Equity:

Common stock, $0.001 par value; 950,000,000 shares authorized; 5,215,709 and 4,511,199
shares issued and outstanding as of September 30, 2024 and December 31, 2023,
respectively

5,216

4,511

Additional paid-in capital

479,024,452

470,521,218

Accumulated deficit

(418,588,975)

(409,072,539)

Nutex Health Inc. equity

60,440,693

61,453,190

Noncontrolling interests

19,337,732

17,652,916

Total equity

79,778,425

79,106,106

Total liabilities and equity

$

438,488,604

$

398,245,497

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

Three Months Ended September 30, 

Nine Months Ended September 30, 

2024

2023

2024

2023

Revenue:

Hospital division

$

71,732,529

$

54,585,263

$

199,366,776

$

155,485,230

Population health management division

7,062,340

8,137,709

22,964,141

22,491,613

Total revenue

78,794,869

62,722,972

222,330,917

177,976,843

Operating costs and expenses:

Payroll and benefits

29,848,083

28,873,144

85,249,302

79,570,519

Contract services

11,657,010

9,035,650

32,481,686

27,972,854

Medical supplies

3,982,598

3,460,130

12,892,904

10,748,214

Depreciation and amortization

4,972,478

4,745,941

13,691,484

12,908,848

Other

6,417,886

9,541,894

23,380,318

25,215,549

Total operating costs and expenses

56,878,055

55,656,759

167,695,694

156,415,984

Gross profit

21,916,814

7,066,213

54,635,223

21,560,859

Corporate and other costs:

Facilities closing costs

–

–

–

217,266

Acquisition costs

–

43,464

–

43,464

Stock-based compensation expense

1,963,518

49,167

1,951,444

2,198,812

Impairment of assets

425,221

–

3,898,856

–

Impairment of goodwill

–

–

3,197,391

–

General and administrative expenses

9,865,330

7,794,808

29,176,130

24,730,168

Total corporate and other costs

12,254,069

7,887,439

38,223,821

27,189,710

Operating income (loss)

9,662,745

(821,226)

16,411,402

(5,628,851)

Interest expense, net

5,381,040

4,098,179

14,879,934

12,081,316

Loss on warrant liability

6,733,552

–

1,072,709

–

Other (income) expense

128,645

(53,206)

(712,049)

70,721

Income (loss) before taxes

(2,580,492)

(4,866,199)

1,170,808

(17,780,888)

Income tax expense (benefit)

4,584,518

(342,259)

5,868,075

(2,068,530)

Net loss

(7,165,010)

(4,523,940)

(4,697,267)

(15,712,358)

Less: net income (loss) attributable to
noncontrolling interests

1,623,303

1,018,451

4,819,169

(1,543,641)

Net loss attributable to Nutex Health Inc.

$

(8,788,313)

$

(5,542,391)

$

(9,516,436)

$

(14,168,717)

Loss per common share:

Basic

$

(1.72)

$

(1.25)

$

(1.91)

$

(3.23)

Diluted

$

(1.72)

$

(1.25)

$

(1.91)

$

(3.23)

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Nine Months Ended September 30, 

2024

2023

Cash flows from operating activities:

Net income (loss)

$

(4,697,267)

$

(15,712,358)

Adjustments to reconcile net loss to net cash from operating activities:

Depreciation and amortization

13,691,484

12,908,848

Loss on warrant liability

1,072,709

–

Impairment of goodwill

3,197,391

–

Impairment of assets

3,898,856

–

Derecognition of goodwill

453,017

–

Stock-based compensation expense

1,951,444

2,198,812

Deferred tax benefit

(1,742,789)

(2,068,530)

Debt accretion expense

804,760

1,251,867

Loss on lease termination

–

58,210

Non-cash lease expense (income)

(280,835)

89,338

Changes in operating assets and liabilities, net of the effects of acquisitions:

Accounts receivable

(4,253,034)

4,444,706

Accounts receivable – related party

549,879

(949,408)

Inventories

1,131,416

850,569

Prepaid expenses and other current assets

(1,360,721)

(3,771,946)

Accounts payable

(7,975,067)

(6,015,250)

Accounts payable – related party

(39,314)

2,228,527

Accrued expenses and other current liabilities

16,698,416

7,519,285

Net cash from operating activities

23,100,345

3,032,670

Cash flows from investing activities:

Acquisitions of property and equipment

(1,908,651)

(10,322,487)

Cash related to sale of business

(361,325)

–

Payments for acquisitions of businesses, net of cash acquired

–

(743,837)

Cash related to deconsolidation of Real Estate Entities

–

(1,039,157)

Net cash from investing activities

(2,269,976)

(12,105,481)

Cash flows from financing activities:

Proceeds from lines of credit

1,132,168

2,340,911

Proceeds from notes payable

7,014,999

16,952,905

Proceeds from convertible notes

–

891,000

Repayments of lines of credit

(1,119,327)

(1,592,714)

Repayments of notes payable

(8,332,482)

(10,557,758)

Repayments of finance leases

(1,923,687)

(2,704,082)

Proceeds from common stock issuance, net issuance costs

9,202,500

–

Proceeds from exercise of warrants

801,000

–

Members’ contributions

960,913

649,550

Members’ distributions

(3,659,228)

(4,335,532)

Net cash from financing activities

4,076,856

1,644,280

Net change in cash and cash equivalents

24,907,225

(7,428,531)

Cash and cash equivalents – beginning of the period

22,002,056

34,255,264

Cash and cash equivalents – end of the period

$

46,909,281

$

26,826,733

 

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for an allocation to noncontrolling interests, (gain)/loss on warrant liability, stock-based compensation, certain defined items of expense, and any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.

Three Months Ended September 30, 

Nine Months Ended September 30, 

2024

2023

2024

2023

Reconciliation of net loss attributable to Nutex Health
Inc. to Adjusted EBITDA:

Net loss attributable to Nutex Health Inc.

$

(8,788,313)

$

(5,542,391)

$

(9,516,436)

$

(14,168,717)

Depreciation and amortization

4,972,478

4,745,941

13,691,484

12,908,848

Interest expense, net

5,381,040

4,098,179

14,879,934

12,081,316

Income tax expense (benefit)

4,584,518

(342,259)

5,868,075

(2,068,530)

Allocation to noncontrolling interests

(1,808,422)

(1,772,908)

(4,980,424)

(3,500,873)

EBITDA attributable to Nutex Health Inc.

4,341,301

1,186,562

19,942,633

5,252,044

Facilities closing costs

–

–

–

217,266

Loss on warrant liability

6,733,552

–

1,072,709

–

Impairment of assets

425,221

3,898,856

Impairment of goodwill

–

–

3,197,391

–

Acquisition costs

–

43,464

–

43,464

Stock-based compensation expense

1,963,518

49,167

1,951,444

2,198,812

Adjusted EBITDA attributable to Nutex Health Inc.

$

13,463,592

$

1,279,193

$

30,063,033

$

7,711,586

 

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 22 facilities in ten states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 and in the Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-third-quarter-and-year-to-date-september-30-2024-financial-results-302299409.html

SOURCE Nutex Health, Inc.

Related Topics:
Continue Reading

Technology

Lubbock Plastic Surgeon Dr. Thanapoom Boonipat Leads Suturing Workshop for Texas Tech Women in STEM Premed Students

Published

3 hours ago

on

October 25, 2026

By

Suturing workshop

LUBBOCK, Texas, Oct. 25, 2026 /PRNewswire/ — Dr. Thanapoom “Mo” Boonipat, plastic surgeon and founder of FacePlus Plastic Surgery Institute in Lubbock, led a hands-on suturing workshop and career Q&A session for premed students at Texas Tech University. The event was organized by Women in STEM at Texas Tech University.

During the workshop, students practiced suturing fundamentals on suture pads using surgical instruments, with Dr. Boonipat demonstrating technique and coaching students individually. The session also included an open discussion about the path to a career in medicine, including medical school, residency training, and choosing a surgical specialty.

“Every surgeon remembers the first time they held a needle driver. Giving premed students that experience early — along with honest answers about the road ahead — can make the path into medicine feel real and reachable. I was glad to spend the afternoon with such motivated students.” — Dr. Thanapoom Boonipat

“Organizations like Women in STEM do important work connecting young women with mentors and hands-on experience in fields where they are still underrepresented, including surgery. FacePlus is proud to support that effort here in our own community in Lubbock.” — Dr. Thanapoom Boonipat

Women in STEM is a Texas Tech University student organization that supports women pursuing undergraduate and graduate studies in science, technology, engineering and mathematics. Events like this connect students with practicing professionals and give them early, practical exposure to clinical skills.

Dr. Boonipat is a plastic and craniofacial surgeon. His training includes an integrated plastic surgery residency at Mayo Clinic and a craniofacial, maxillofacial, and facial aesthetics fellowship at Chang Gung Memorial Hospital in Taiwan, following medical school at Dartmouth and undergraduate study in biomedical engineering at Johns Hopkins. He founded FacePlus Plastic Surgery Institute in Lubbock in 2024.

About FacePlus Plastic Surgery Institute:
FacePlus Plastic Surgery Institute is a plastic surgery practice in Lubbock, Texas, founded by Thanapoom Boonipat, MD. The practice provides cosmetic and reconstructive plastic surgery, including facial, breast, and body procedures, serving patients in Lubbock and across West Texas. For more information, visit facepluspsi.com.

Media Contact:
FacePlus Plastic Surgery Institute
moboonipatmd@facepluspsi.com
(806) 503-2090
Lubbock, Texas

Press Release Service provided by 24-7PressRelease.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lubbock-plastic-surgeon-dr-thanapoom-boonipat-leads-suturing-workshop-for-texas-tech-women-in-stem-premed-students-302918808.html

SOURCE FacePlus Plastic Surgery Institute

Continue Reading

Technology

Vantrue Announces Early Black Friday Sale with Up to 44% Off Select Dash Cams

Published

6 hours ago

on

October 25, 2026

By

November 1–21, 2026 | Official Website: Vantrue.com

SHENZHEN, China, Oct. 25, 2026 /PRNewswire/ — Vantrue, a dash cam brand dedicated to helping drivers capture the road with confidence, is launching its three-week Black Friday campaign from November 1 to November 21, 2026. The event brings together discounts of up to 44% on selected dash cams, a 100% win-rate prize wheel for subscribers, and exclusive bidding events, giving drivers multiple ways to discover and save on Vantrue products.

Every Eligible Spin Wins a Prize

The Black Friday excitement starts with Vantrue’s 100% win-rate spin wheel. Visitors can subscribe through the official website and spin for a chance to receive exciting rewards, including the latest Vantrue dash cams, special prize bundles, and other surprises. Each subscriber is eligible for one spin during the campaign.

Black Friday Deals in Two Waves

Vantrue’s Black Friday offers will roll out in two waves, featuring discounts on selected dash cams for everyday drivers, rideshare professionals, and those looking to upgrade their in-car recording setup.

Wave 1: November 1–10, 2026

Vantrue E1 Lite: 36% off — $69.99 (regular price: $109.99)
 Vantrue N2X: 36% off — $159.99 (regular price: $249.99)
 Vantrue N4S: 44% off — $199.99 (regular price: $359.99)
 

Wave 2: November 11–21, 2026

Vantrue E1 Pro S: 35% off — $129.99 (regular price: $199.99)
 Vantrue N5S: 36% off — $293.99 (regular price: $459.99)
 Vantrue N4 Pro S: 40% off — $279.99 (regular price: $469.99)
 

Exclusive Bidding Events Add More Excitement

In addition to the promotional pricing, Vantrue will host two special bidding events, offering participants another way to pursue selected dash cams at competitive prices.

BID #1: November 5–7, 2026 — Bid on featured products for a chance to secure them at a lower price.BID #2: November 12–14, 2026 — Return for another opportunity to bid on premium models.

With multiple ways to participate throughout the three-week event, Vantrue’s Black Friday campaign combines savings, interactive rewards, and special shopping opportunities in one destination.

Join Vantrue’s Black Friday Event

From November 1 through November 21, 2026, drivers can explore the latest offers, take part in the prize wheel, and join the bidding events through Vantrue’s official website.

Visit https://www.vantrue.com/ for campaign details and product offers.

About Vantrue

Founded in 2015, Vantrue is a leading global dash cam brand dedicated to providing intelligent, reliable, and user-centric driving solutions. With a focus on innovative technology, dependable performance, and user-friendly design, Vantrue develops dash cams for everyday drivers, families, and professionals on the road. Committed to helping drivers capture every journey with greater confidence and peace of mind, Vantrue continues to innovate to make every drive safer and every moment worth capturing.

Media Contact
Vantrue Media Relations
Email: support@vantrue.net
Website: https://www.vantrue.com

View original content:https://www.prnewswire.com/news-releases/vantrue-announces-early-black-friday-sale-with-up-to-44-off-select-dash-cams-302918196.html

SOURCE Vantrue

Continue Reading

Technology

LexisNexis Coplogic Solutions Introduces Field Clarity for LexisNexis® Desk Officer Reporting System (DORS) at IACP 2026

Published

9 hours ago

on

October 25, 2026

By

A new, modern DORS and Field Clarity, the First AI-Guided Smartphone Video Assistant, Enhances Community Experience and Helps Improve Evidence, Case Building

ORLANDO, Fla., Oct. 25, 2026 /PRNewswire/ — LexisNexis® Coplogic™ Solutions today announced its modernized LexisNexis® Desk Officer Reporting System (DORS) community online reporting solution and the addition of DORS with Field Clarity, an AI-guided video assistant designed to improve field documentation accuracy and enable faster resolution by law enforcement agencies (LEAs). Field Clarity is designed to help community members submit reports to their local LEAs using DORS via intuitive step-by-step instructions. A hands-on experience for DORS with Field Clarity will be available for demonstration during the 2026 International Association of Chiefs of Police (IACP) annual conference.

“Agencies generally look to strategic partners like us not just for technology, but also for relief, reinforcement, and credibility across three tightly connected challenges: public expectation, workforce strain and digital evidence overload,” said Jason LaRue, associate vice president, LexisNexis Coplogic Solutions. “Our modernized LexisNexis Desk Officer Reporting System (DORS) helps agencies improve officer safety along with community member experiences. Field Clarity strengthens video evidence quality and digital evidence management to reduce friction and alleviate strain on a challenged workforce.”

Key Highlights
Integrated into LexisNexis® Desk Officer Reporting System (DORS), Field Clarity is the first AI-Guided video assistant for community member online reporting that:

Transforms data capture from passive intake into intelligent, guided capture to help create more positive officer and civilian mobile-first experiencesDrives more accurate field documentation, evidence and case building to help with faster resolution and enhanced public safetyBenefits civilians submitting reports with intuitive, step-by-step instructions, almost like having a digital assistant with them in real timeBenefits officers by bringing video, photos and scanned data together for a clearer picture of an event without the need to track down additional details

How the DORS with Field Clarity Solution Works
DORS allows each law enforcement agency to collect information directly from civilians on more than 200 incident types based on the needs of their community. DORS and Field Clarity make the filing of an online report experience easier by guiding users intuitively through each step of the process on their smartphone device, similar to having a personal digital assistant. Instead of asking a driver, for example, to fill out forms and guess what’s needed, the Field Clarity conversational interface prompts them to scan their driver’s license, capture a VIN or record a short walkaround video explaining what happened during the incident, all while capturing the data necessary to complete the report.

For civilians, being able to easily film on-scene evidence means less confusion and need for reentries or follow-up by the sworn officer responsible for approving reports. For officers, the benefits include cleaner, more complete accident reports and less time spent requesting and gathering additional details. With reports fed directly into the agency’s Record Management System (RMS), law enforcement also benefits from more efficient workflows and stronger documented cases for their investigators. DORS is used by nearly 600 agencies in North America, saving agencies approximately 900,000 personnel hours and $90 million annually*

“Trust in law enforcement is built one interaction at a time. Every opportunity for a community member to engage with their police department matters, including something as routine as filing a report,” said Sarah E. Connolly, co-founder of Guardian Communications, FBI-LEEDA instructor and retired Baltimore Police lieutenant and PIO. “When technology makes that process easier, improves the quality of information collected and supports a more responsive agency, it has the potential to do more than improve efficiency. It can help strengthen the relationship between law enforcement and the communities they serve.”

LexisNexis Coplogic Solutions delivers solutions and capabilities that can create a clearer line of sight from the field to law enforcement leadership, strengthening the connection between daily operations, workforce support, data management and community trust. DORS with Field Clarity is available through LexisNexis® Command Center, a single access point to the LexisNexis Coplogic Solutions data and analytics solutions suite, including LexisNexis®  BuyCrash®, LexisNexis® eCrash and LexisNexis® eCitation solutions. Coplogic Solutions also offers Unified Performance Dashboards for crash and citation mapping and illustrated visualizations, which connect field data with contextual insight in a single, coherent view – so law enforcement leaders can better understand and more confidently explain to their communities not just what is happening in near-real time, but also why. 

To speak with Coplogic law enforcement experts about LexisNexis Desk Officer Reporting System (DORS) with Field Clarity and experience the solution firsthand, visit LexisNexis Coplogic Solutions at IACP Booth #941, October 24 – 27, 2026 in Orlando, Florida. To learn more, check out this video: LexisNexis® Desk Officer Reporting System (DORS).

About LexisNexis Risk Solutions
LexisNexis® Risk Solutions provides customers with information-based analytics and decision tools that combine public and industry-specific content with advanced technology and algorithms to assist them in evaluating and predicting risk and enhancing operational efficiency. Headquartered in metro Atlanta, Georgia, the company has offices throughout the world, serves customers in more than 190 countries and territories and is part of RELX. For more information, please visit LexisNexis Risk Solutions.

About LexisNexis Coplogic Solutions
LexisNexis® Coplogic™ Solutions is committed to meeting law enforcement agencies where they are on the road to saving more lives and helping take them where they want to be by delivering an innovative full suite of data sophistication solutions to create workflow efficiencies while delivering world-class crash and citation data and analytics visualizations through advanced technology. Our proven solutions, developed by and specifically for law enforcement, can help agencies operate more effectively, increase services to their communities and improve traffic and overall public safety through electronic, mobile-first authoring capabilities, web-based eCommerce solutions, analytics and more. For more information, please visit risk.lexisnexis.com/Coplogic.

Media Contacts: 
Chaz Abbott
LexisNexis Risk Solutions
chaz.abbott@lexisnexisrisk.com
+1 949.922.1167

*Based on a 2025 LexisNexis Coplogic Solutions internal study

View original content to download multimedia:https://www.prnewswire.com/news-releases/lexisnexis-coplogic-solutions-introduces-field-clarity-for-lexisnexis-desk-officer-reporting-system-dors-at-iacp-2026-302918694.html

SOURCE LexisNexis Risk Solutions

Continue Reading

Trending